Exelixis Inc Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate
Exelixis Inc (EXEL) had Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate of 50.00% as of 2018-12-28, per its 10-K filed 2019-02-22.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate · last filed 2019-02-22
- 2018-12-28: Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate 50.00%.
- 2017-12-29: Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate 50.00%.
- 2016-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate 50.00%.
- 2015-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate 50.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate |
|---|---|
| 2018-12-28 | 50.00% 10-K · filed 2019-02-22 |
| 2017-12-29 | 50.00% 10-K · filed 2018-02-26 |
| 2016-12-31 | 50.00% 10-K · filed 2017-02-27 |
| 2015-12-31 | 50.00% 10-K · filed 2016-02-29 |
| 2014-12-31 | 50.00% 10-K · filed 2015-03-02 |
| 2013-12-31 | 50.00% 10-K · filed 2014-02-20 |
| 2012-12-31 | 50.00% 10-K · filed 2013-02-21 |
| 2011-12-31 | 20.00% 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |